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Abstract
Cannabinoid receptors in the brain appear to be intimately involved in the motor control.
Cannabinoid CB1 receptors are densely located in the basal ganglia (BG), a forebrain
system that integrates cortical information to coordinate motor activity regulating signals.
In fact,  the administration of plant-derived,  synthetic or endogenous cannabinoids
produces several effects on motor function. These effects are paralleled to changes in the
levels of different neurotransmitters in the BG, including GABA, dopamine and glutamate,
all of which are important players in movement control.
Cannabinoid receptors also participate in the etiopathology of movement disorders such
as Parkinson’s disease (PD) or Huntington’s disease (HD). In fact, both CB receptors and
endocannabinoid levels are altered in the BG of patients with PD and HD and animal
models of these diseases. The benefit of cannabinoids in PD or HD is not limited to the
symptomatic  amelioration,  since  several  publications  have  revealed  interesting
neuroprotective and anti-inflammatory effects of these drugs. It has been suggested that
cannabinoid modulation may constitute an important component in new therapeutic
approaches to the treatment of motor disturbances.
Keywords: Basal Ganglia, endocannabinoids, Parkinson's disease, Huntington's dis‐
ease, CB1 receptor, CB2 receptor, TRPV1
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∆9-THCV: ∆9-Tetrahydrocannabivarin
2-AG: 2-Arachidonoylglycerol
3-NP: 3-nitropropionic acid
6-OHDA: 6-hydroxidopamine
AEA: Anandamide
BDNF: Brain-derived neurotrophic factor
BG: Basal Ganglia
CAG: Cytosine-adenine-guanine
CBD: Cannabidiol
CNS: Central nervous system
ECS: Endocannabinoid system
FAAH: Fatty acid amide hydrolase
HD: Huntington’s disease
HTT: huntingtin protein
Internal/external globus pallidus: GPi/GPe
LPS: Lipopolysaccharide
MAGL: Monoacylglycerol lipase
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
PD: Parkinson’s disease
PEA: Palmitoylethanolamide
SNc: Substantia nigra pars compacta
SNr: Substantia nigra pars reticulata
SPN: Spiny projection neurons
STN: Subthalamic nucleus
TRPV1: Transient receptor potential vanilloid 1
VGLUT1: vesicular glutamate transporter 1
VGLUT2: vesicular glutamate transporter 2
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1. Introduction
The identification of more than 60 oxygen-containing aromatic hydrocarbon compounds,
known as cannabinoids in the plant Cannabis sativa, led to the discovery of the endocannabi‐
noid system (ECS) [1]. This system consists of two well-characterized seven transmembrane
G-protein coupled receptors, CB1 [2] and CB2 [3], the transient receptor potential vanilloid 1
(TRPV1) channel, a number of endogenous ligands and associated enzymes for biosynthesis
and degradation (for review see [4,5]). The endocannabinoids are lipids localized in the central
nervous system (CNS) and peripheral tissue, being anandamide (AEA) and 2-arachidonoyl‐
glycerol (2-AG) the best characterized ones [4]. These endocannabinoids are synthesized, on
demand, after neuronal depolarization, released into the extracellular space and after CB
receptors activation they are uptaken by a specific transport protein located on both neurons
and glial cells to be subsequently degraded by intracellular enzymes [6].
The CB1 receptor is one of the most abundant cannabinoid receptor in the neurons from the
CNS whereas the CB2 receptor is more predominant in glial cells and peripheral tissues [7].
CB receptors are coupled to Gi/o proteins, negatively to adenylyl cyclase and positively to
mitogen-activated protein kinase and ion channels. Thereby activation of these receptors exerts
diverse responses as inhibition of neurotransmitter release including GABA, glutamate,
noradrenalin and dopamine [6,8,9], gene transcription and cell proliferation, differentiation
and survival [10]. Commonly, the ECS is described as a neuromodulatory system which
interacts with other neurotransmitter systems and may be implicated in (patho)physiologi‐
cal functions among others, those related to motor activity, neuron proliferation and inflam‐
matory process. Consequently the ECS appears as a promising target for drug development.
Cannabis sativa derivatives have been used medically for thousands of years, however the
psychoactive effects together with tolerance and its potential abuse have limited the clinical
application. Nowadays numerous efforts are being made to develop non-psychotropic
cannabinoids that could be used in several CNS disorders.
This review will focus on recent studies clarifying the role of the ECS as a target to develop
new therapeutic tools to treat movement disorders.
2. Neuroanatomical distribution of the endocannabinoid system in the BG
The ECS is highly expressed in the Basal Ganglia (BG), which is a highly organized network
of subcortical nuclei composed of the striatum (caudate and putamen), subthalamic nucleus
(STN), internal and external globus pallidus (or entopeduncular nucleus in rodents, GPi/EP and
GPe) and substantia nigra (pars compacta, SNc, and pars reticulata, SNr). The BG connects the
cortex with the thalamus, creating the cortico–basal ganglia–thalamo–cortical loop, and plays
a crucial role on controlling movement activity.
High levels of CB1 receptors are found in the striatum and motor cortex where they are mainly
present in projecting terminals (reviewed in [11]). Thus, CB1 receptors have been observed in
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glutamatergic corticostriatal afferences [12,13], striatal projections to the GPi/GPe and to the
SNr [14,15] and also in subthalamonigral and subthalamopallidal terminals [15,16]. Moderate
to dense CB2 immunoreactivity is also present in the cortex, striatum and SN [17] and is
increased in several pathological conditions [18,19]. TRPV1 receptors have also been located
in nigrostriatal terminals and on tyrosine hydroxylase-positive cells in the SNc [20,21].
The two most important endocannabinoid-synthesizing enzymes (N-acyl phosphatidyletha‐
nolamine phospholipase D and diacylglycerol lipase-alpha) as well as the endocannabinoid
degradative enzymes (fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase
(MAGL)) are found in the BG, particularly in the striatum [22–24]. Finally, both AEA and 2-
AG are expressed within the BG and modulate the activity of the cortico–basal ganglia–
thalamo–cortical loop leading to motor activity modulation (for review see [25]).
3. Motor effects of cannabinoids
Over the last three decades a wide range of experimental and clinical studies have demon‐
strated that the ECS plays a key role controlling motor function. Specifically, three lines of
evidence support this idea. First, administration of plant-derived compounds, synthetic
cannabinoids and endocannabinoids produces a variety of effects on motor activity in humans
and laboratory animals. Second, endocannabinoids and their receptors are abundant in the BG
and the cerebellum, two brain areas that exert direct control of motor function. Third,
biochemical and functional alterations of the ECS have been related to the etiology of several
movement disorders, since overactivity of the ECS signaling is associated with the progres‐
sion of the nigral degeneration in patients with Parkinson’s disease (PD) [26–28] and down-
regulation of CB1 receptors has been reported in brain samples collected from patients with
Huntington’s disease (HD) [29–31].
Marijuana consumption affects psychomotor skills clearly reflected in poor performance of
highly demanding tasks and potent impairment of motor coordination [32–34], interfering
with driving skills and increasing the risk of injuries [35]. In experimental animal models, the
motor effects of the endogenous ligand AEA are similar to those induced by the plant-derived
cannabinoid agonist Δ9-tetrahydrocannabinol (Δ9-THC), but less pronounced and of shorter
duration. The main motor outcomes of cannabinoid agonists are hypoactivity and catalepsy,
however biphasic effects have been described depending on the drug and dose used. While
relatively low doses of Δ9-THC and AEA have been associated with a transient increase in
motor activity, high doses produce motor inhibition and catalepsy [36–45]. Additionally, both
drugs AEA and Δ9-THC potentiate the catalepsy induced by a local administration of muscimol
into the GP [46] and reduce stereotyped behaviors [40–42]. Δ9-THC reduces the ampheta‐
mine-induced hyperlocomotion [47] and impairs fine motor control in rats [48].
Interestingly, cannabidiol (CBD), other plant-derived cannabinoid, has been proposed as a
modulator of the effects induced by Δ9-THC (reviewed in [49]). Several studies conclude that
CBD attenuates some Δ9-THC motor side effects such as catalepsy [50–52], while others show
that high doses of CBD fail to prevent or exacerbate the pharmacological effects of Δ9-THC,
Cannabinoids in Health and Disease62
including hypoactivity [45,53]. Nevertheless, the influence of CBD on spontaneous locomo‐
tion seems to be limited [45,53–55] and it may be unrelated to the CB receptors interaction [49].
Preclinical studies using synthetic cannabinoid agents have highlighted the role of the ECS on
the control of motor function. Thus, systemic administration of the agonists WIN 55,212-2,
CP55,940 and HU210 usually causes inhibition of motor activity [45,56–61] and produces basal
catalepsy [52,62–64]. Activation of CB1 receptors by the agonist CP55,940 enhances the
catalepsy induced by dopaminergic antagonists [65] and genetic inactivation of either
dopamine D2 receptors or adenosine A2A receptors reduces the motor depression produced
by CP55,940 [63]. In fact, the inhibitory motor effects caused by an intrastriatal injection of the
CB1 agonist WIN 55,212-2 are mediated by a functional interaction between the adenosine
A2A and the CB1 receptors [66], which are present as heteromers in the rat corticostriatal
terminals [67]. In line with this, the specific adenosine A2A receptor antagonist MSX-3 blocks
the inhibitory effect of the CB1 receptor agonist CP 55,940 on the hyperactivity induced by the
dopamine D2 receptor agonist quinpirole [58]. Although, a strong functional interaction
between striatal A2A and CB1 receptors is accepted, the mechanisms of this interaction are
still not clear since it has been proposed a stimulatory role as well as an inhibitory role of A2A
receptors on CB1 receptor-dependent effects [68].
Pharmacological agents that indirectly elevate endocannabinoid levels by inhibiting either
their uptake or the intracellular degradation have been proposed as promising therapeutic
agents for the treatment of diverse diseases including movement disorders (for review see
[69]). These pharmacological agents are also referred as indirect agonists and they also elicit
some cannabimimetic motor effects, including hypoactivity. On one hand, the selective and
potent inhibition of the endocannabinoids transport by the arachidonic acid derivative,
UCM707 potentiates the hypokinetic effects caused by a non-efficacious dose of AEA [70].
Similarly, the selective blockade of the AEA transport by AM404 elevates circulating levels of
the endocannabinoid and causes hypoactivity [71,72], likely by activating TRPV1 [73]. On the
other hand, selective inhibition of the endocannabinoids metabolizing enzymes has brought
interesting results suggesting the differential role of the endogenous agents, AEA and 2-AG,
in the unwanted motor effects induced by cannabinoid compounds. Specifically, inhibition of
MAGL, but not FAAH, causes CB1 receptor-mediated hypoactivity. However, neither FAAH
nor MAGL produce cataleptic effects usually elicited by direct agonists [74,75]. Thus, the
FAAH inhibitor URB597 does not significantly alter motor function at doses that induces
analgesia [74] and a single or repeated administration of PF-04457845, a specific and irrever‐
sible FAAH inhibitor, is well tolerated in healthy humans [76]. Conversely, the MAGL inhibitor
JZL184 reduces locomotor activity [77,78], and dual inhibitors JZL195 and AS-57 induce also
catalepsy [75,79].
From a general point of view, the motor effects of direct and indirect agonists are usually
mediated by stimulation of CB1 receptor since its pharmacological blockade prevents the
above mentioned effects [64,72,75,80,81]. In addition, a high dose of the CB1 receptor antago‐
nist SR141716A causes hyperlocomotion by itself [82,83] while a lower dose does not affect
motor activity [84]. Also the CB1 receptor antagonist AM251 administrated alone fails to alter
basal locomotion but diminishes the psychomotor effects induced by the co-administration of
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amphetamine [85]. In agreement with these observations, mice lacking CB1 receptors exhibit
several motor anomalies [86,87] and show less sensitivity to the psychomotor stimulants and
sensitizing effects of the psychostimulants [88,89].
Although these findings provide evidence for the involvement of CB1 receptor-related
mechanisms in motor control, other reports demonstrate that also the TRPV1 receptors can
mediate effects of certain cannabinoids such as AEA [90]. The potential beneficial effects of
cannabinoid agents in movement disorders are further reviewed here.
4. Alterations of the endocannabinoid system in movement disorders
4.1. Endocannabinoid system in Parkinson’s disease
PD is the second most common neurodegenerative disorder, after Alzheimer’s disease. It is a
chronic and progressive neurodegenerative illness and its etiology is interpreted as a combi‐
nation of genetic, environmental, and aging-related processes, although the exact cause of this
degeneration is unknown. Clinical manifestation of the disease includes tremor at rest,
worsening of voluntary movements, bradykinesia, muscle rigidity and postural instability
[91,92]. All of these symptoms appear as a result of pathological processes, including neuro‐
inflammation, mitochondrial dysfunction, oxidative stress, kinase pathways and calcium
dysregulation, protein aggregation and prion-like processes, which result in a degeneration
of dopamine neurons in the SNc and a subsequent dopaminergic depletion in the striatum,
the main input nucleus of the BG neural circuit. [93].
Several components of the ECS are altered in movement disorders which have led to consid‐
er it as a possible target for developing new treatments for these disorders. The effects of
cannabinoid compounds and their potential utility in PD has been tested, but inconsistent data
have been produced, as there are many complex responses elicited by dopamine and its
interaction with different cannabinoid mechanisms [94].
4.1.1. Endocannabinoid levels
The ECS in the BG becomes overactivated in PD. For instance, the cerebrospinal fluid of
untreated patients with PD has at least two-fold higher levels of AEA, compared to controls,
being this increase independent of either disease stage or progression [27]. Overall, results
from preclinical studies support the clinical findings.
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys, the levels of both
AEA and 2-AG were determined throughout the BG after induction of parkinsonism and L-
DOPA treatment. Both AEA and 2-AG levels were elevated in the striatum of untreated
parkinsonian monkeys and returned to those found in the striatum of normal monkeys after
treatment with L-DOPA [95]. These results are similar to those reported in rodent models of
PD, where AEA levels were estimated to be higher in the BG output regions, as compared to
the striatum or GPe, while 2-AG levels were similar throughout the BG regions analyzed [96].
Similarly, in a rat model of PD induced by unilateral nigral lesion with 6-hydroxidopamine
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(6-OHDA), striatal levels of AEA, but not 2-AG levels, were increased. Moreover, decreased
activity of the AEA membrane transporter and FAAH was observed, whereas the binding of
AEA to CB receptors was unaffected [97]. In studies with reserpine-treated rats an increase
of 2-AG levels in output BG regions, such as GP and SNr has been reported compared to other
brain regions like the cortex, cerebellum, hippocampus, and striatum [98]. In mutant models
of the disease, as the homozygous Pink1 knockout mice, the levels of 2-AG and AEA were not
altered in striatum, and no change was observed as for the activity of FAAH and MAGL,
responsible for endocannabinoids hydrolysis. Although the levels of 2-AG remains un‐
changed in PD, this endocannabinoid has revealed its neuroprotective role in the MPTP mouse
model [99] as well as palmitoylethanolamide (PEA) [100].
4.1.2. Cannabinoid receptors
CB1 availability is unevenly modified in patients with PD, which is decreased in the SN but
relatively increased in nigrostriatal, mesolimbic, and mesocortical dopaminergic projection
areas [101]. In post-mortem samples from patients with PD increased CB1 receptor binding in
the caudate-putamen was found and a higher stimulation by CB1 receptor agonists of
[35S]GTPγS binding was measured in the same brain areas [26]. Other studies performed in
PD human brain have shown that the expression of CB1 receptor mRNA was decreased in the
caudate nucleus, anterior dorsal putamen and GPe, but remained unchanged in the other brain
areas examined [102]. When the relationship between CB1 receptors and dopamine D2/D3
receptor densities was analyzed by receptor autoradiography, unchanged CB1 receptor
density in the putamen and caudate of patients with PD (treated with L-DOPA) was found
together with a parallel decreased in the density levels of dopamine D2/D3 receptors in the
same nuclei [103].
Studies in animal models also show disparity of results concerning CB1 receptors. In MPTP-
lesioned marmosets, increase in CB1 receptor binding was also confirmed in the caudate-
putamen [26]. In contrast, in the reserpine-treated rat model of PD a topographically organized
reduction in CB1 receptor mRNA expression in the striatum was found [98]. However, in other
studies with 6-OHDA-lesioned rats, no significant change in CB1 receptor expression or
binding was detected, although an increase in CB1 receptor mRNA levels in the striatum was
found [104,105]. In Pink1 knockout mice, however, a significant reduction of binding ability of
CB1 receptor agonists was found [106].
Regarding CB2 receptors, in neurotoxin rat models of PD, when 6-OHDA or lipopolysacchar‐
ide (LPS) is injected into the striatum, increased expression of the CB2 receptor and propor‐
tionally increased microglial activation was found [107]. Other CB receptors may have a role
in PD treatment, thus the pharmacological blockade of TRPV1 receptors, which have been
implicated in the modulation of dopamine transmission in the BG, attenuates the 6-OHDA
induced hypokinesia [108]. TRPV1 receptors, where AEA binds, may play opposite roles to
CB1 receptors in order to treat L-DOPA-induced dyskinesia [94,109]. Although it seem that
the ECS suffers dramatic modifications in PD, so far clinical and preclinical studies show no
conclusive results.
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4.2. Endocannabinoid system in Huntington’s disease
HD is a rare autosomal-dominant progressive neurodegenerative disease that affects 4–10
per 100,000 people in Western countries [110]. It is caused by the mutation in the IT15 gene
(HTT) that encodes the huntingtin protein(HTT) and consists in an expanded cytosine-
adenine-guanine (CAG) repeat that yields an abnormally long polyglutamine sequence in
HTT [111]. Healthy subjects have less than 35 CAG repeats, while genes with more than 39–
40 CAG repeats (or more) encode pathogenic HTT. Although physiological HTT is widely
found in the brain, the mutation leads to the expression of the aberrant protein harmful only
to specific neuron populations. Indeed, the prominent degeneration of GABAergic spiny
projecting neurons (SPN) in the striatum [112] and to a lesser extent, of glutamatergic cortical
pyramidal neurons [113,114] are the hallmarks of the disease. In late stages of the disease other
brain areas and neurons may also be affected, producing a complex disease. The clinical
manifestation can appear early, at the ages of 30–50 years, and progressively worsen over the
following years. On the course of the disease, the patient can suffer from movement disor‐
ders, cognitive disability and psychiatric symptoms such as personality changes, depression
or memory loss, among others [115]. The early stages of the disease are characterized by choreic
involuntary movements and cognitive impairment, which are related to mutant HTT aggre‐
gation and aberrant neurotransmission in the striatopallidal SPN and corticostriatal neurons,
respectively (reviewed in [116]). In more advanced phases of the disease, when the direct
pathway in the BG is also affected, the patients display parkinsonian-like symptoms, as
bradykinesia and rigidity [117].
4.2.1. Endocannabinoid levels
As mentioned for PD, in HD The ECS also suffers notorious modifications on the course of the
disease in the BG [30,31,118]. In post-mortem tissue, higher expression of FAAH was ob‐
served in the caudate-putamen from HD brains [119] while the opposite effect was found in
the cortex [120].
The activity of the ECS has also been investigated in animal models of HD without consis‐
tent results, probably due to the different models and ages selected for the studies. In the R6/1
transgenic model of HD, significant decrease in AEA levels were detected in the hippocam‐
pus in contrast to increased 2-AG concentrations only found in the cortex at 12 weeks of age,
prior to the motor disturbances [121]. Another study in R6/2 transgenic mice, which differ in
CAG repeats number from R6/1 mice and show severe motor and cognitive defects at earlier
ages, also reported decreased in cortical 2-AG during motor presymptomatic stages [122]. In
symptomatic R6/2 mice, AEA, 2-AG and PEA were markedly decreased in the striatum and
in a lesser extent in the hippocampus or cortex [122]. Other study performed also in R6/2 mice
found increased 2-AG but unchanged AEA levels in the striatum [123]. As for the enzymes’
activity, Bari et al. found increased FAAH and decreased MAGL activity in the cortex together
with reduced activity of AEA and 2-AG metabolic-enzymes at different ages in the striatum,
which disagrees with the higher expression of FAAH reported by others [119]. The use of other
animal models, such us the 3-nitropropionic acid (3-NP)-lesion rat, showed decreased AEA
and 2-AG in the striatum but suggested increased AEA levels in the SN [124].
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So far studies regarding enzyme activity and endocannabinoid levels in HD are limited and
offer inconsistent results although overall endocannabinoid levels seem to be reduced in dif‐
ferent brain areas. More homogeneous preclinical studies together with clinical investiga‐
tions will be needed for clarifying these founds.
4.2.2. Cannabinoid receptors
Autoradiographical and immunohistochemical studies in human post-mortem tissue demon‐
strated that early stages of the disease are characterized by a loss of CB1, dopamine D2 and
adenosine A2A receptors in the caudate nucleus, putamen and GPe, which corresponds to the
deterioration of striatopallidal SPNs [30,118,125]. Later in the disease, when the striatonigral
pathway also degenerates, even greater down-regulation of striatal and nigral CB1 receptors
is observed [30]. In vivo imaging of CB1 in patients confirmed the down-expression of these
receptors in cortical and subcortical structures, starting early in the development of the
disease [126]. Despite the variety of animal models available for studying the disease, most
preclinical studies back up the observations from human tissue. In transgenic mice, such as
the HD94 or R6/2 transgenic models, loss of mRNA levels, binding, receptor expression and
activation of GTP-binding proteins for cannabinoid CB1 receptors have been reported
primarily in SPNs belonging to the indirect pathway in the early phases of the disease
accompanied or not by cortical and hippocampal alterations [121,123,125,127–129]. In models
induced by the administration of 3-NP, where striatal neuronal loss is produced, additional
loss of CB1 receptors is also observed [124,130,131]. Small animal PET studies performed in
transgenic HD rat and mouse models, have also confirmed reduced CB1 receptor binding in
the striatum and GPe in all stages, as well as alterations in the cortex, hippocampus, thala‐
mic nuclei or cerebellum in more advanced phases of the disease [132,133]. Results from human
brain and most animal models coincide in reporting down-regulation of striatal CB1 recep‐
tors in HD, which has been proposed to be induced by mutant HTT that controls gene promoter
activity via repressor element 1 silencing transcription factor [119]. In this respect, genetic CB1
receptor deletion has been proven to worsen motor symptomatology and to exacerbate striatal
degeneration by increasing excitotoxic damage and decreasing brain-derived neurotrophic
factors [119,134,135]. Although rescuing CB1 receptors prevents the striatal morphological
modifications observed in mice models of HD, it failed to improve motor deterioration [136].
Regarding CB2 receptors in the HD brain, studies performed in post-mortem human tissue
suggest up-regulation of CB2 receptors on CD68-positive microglial cells [137] or slight
increase on brain blood vessels [138] but not on astrocytic cells. These results agree in part with
preclinical studies where up-regulation of CB2 receptors has been observed in the striatal
microglial of R6/2 mice and striatal microglia and astrocytes in a rat model of HD induced by
intrastriatal injection of malonate (mitochondrial complex II inhibitor) [137,139]. This com‐
pensatory increase of CB2 receptors may have a neuroprotective effect on the disease [137]. In
this line, CB2 agonists have been proposed to decrease striatal neurodegeneration in malo‐
nate-lesioned rats [139]. In addition, CB2 depletion has been documented to accelerate the
onset of the disease and aggravate the motor disabilities in a mouse model of HD [137,140].
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Less attention has been paid to the TRPV1 channels, which also play an important role in the
ECS. So far, only one publication has studied these receptors reporting no modification in
TRPV1 binding in R6/2 mice at any age [123].
In general, preclinical and clinical studies have well characterized a down-regulation of CB1
receptors at different stages of HD, which may cause a role in the progression of the disease.
Less is known about CB2 or TRPV1 receptors and further investigations are required to clarify
their role in the neuropathology of the disease.
5. Potential therapeutic role of cannabinoids in movement disorders
5.1. Parkinson’s disease
Currently, pharmacological treatment for PD is focused on dopaminergic replacement, which
controls the symptoms in both early and advanced stages [141]. However, its chronic use is
limited due to the development of severe and disabling side effects, such as motor fluctua‐
tions or L-DOPA-induced dyskinesia. Besides, none of the available treatments are capable of
slowing or stopping the disease progression. Cannabinoid-based therapies have been
proposed as a promising approach for PD treatment, not only for their antiparkinsonian
properties, but also for the neuroprotective and anti-inflammatory effects of these compounds.
5.1.1. Cannabinoids for the treatment of motor symptoms
Studies in animal models and patients with PD have indicated that both CB1 agonists and
antagonists used alone or as coadjuvants, could be useful to treat different symptoms of this
movement disorder. Thus, CB1 agonists have been shown to improve motor impairment in
animal models of PD [142–145] and to reduce tremor associated with the hyperactivity of the
STN [145,146]. However, because of the hypokinetic profile of the cannabinoid agonists, it is
unlikely that these drugs would be useful for alleviating bradykinesia in PD patients. In fact,
the administration of agonists to humans or MTPT-lesioned primates enhanced motor
disability (for review [34]).
On the other hand, behavioral changes in parkinsonian rodents also improved with the
administration of CB1 antagonists [147–149]. It has been suggested that blocking CB1 receptors
could be useful in particular conditions, as when the patients do not respond to dopaminer‐
gic therapy or in advanced phases of the disease [147,148,150]. It is also important to consid‐
er the therapeutic benefits of TRPV1 receptor antagonists, given their role in regulating
dopamine release from nigral neurons [151].
Cannabinoids also may be beneficial in treating L-DOPA-induced dyskinesia. Indeed,
administration of CB1 agonists to parkinsonian rats chronically treated with L-DOPA reduced
the occurrence of dyskinesia [109,152,153] without reducing the efficacy of L-DOPA to improve
motor performance. In MPTP-lesioned monkeys and patients with PD the results are mixed.
Indeed, both CB1 agonist and antagonists showed antidyskinetic effect [95,154–157] while
plant-derived cannabinoids failed to improve motor disability [158,159].
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5.1.2. Cannabinoids as neuroprotective agents
In vivo as well as in vitro preclinical studies in animal models of PD have revealed that
cannabinoid receptor modulation can be potentially useful for protecting dopaminergic
neurons from progressive neurodegeneration. Although CB1 receptor-mediated effects cannot
be excluded, some authors argue that CB1 receptors may have a minimal implication in
neuroprotection [10,160–162]. It seems plausible that neuroprotection is principally mediat‐
ed by the antioxidant properties of the cannabinoids [160,163,164], given that oxidative stress
is a major hallmark in the pathogenesis of PD. The effect of numerous phytocannabinoids, as
∆9-THC, CBD and ∆9-Tetrahydrocannabivarin (∆9-THCV), has been investigated in experi‐
mental models of PD (6-OHDA-lesioned rodents, MPTP or LPS-lesioned mice) [160,163,165].
These studies have showed that cannabinoids could be useful for developing novel neuro‐
protective therapies in PD due to their CB receptors-independent antioxidant actions. Double-
blind trial carried out in patients with PD tried to evaluate the neuroprotective effect of CBD
administration but definitive conclusions were not established [166].
Neuroprotection has also been provided by synthetic cannabinoids such as the endocannabi‐
noid transporter inhibitor/vanilloid agonist AM404, or the CB1/CB2 receptors agonist
CP55,940, which also produce antioxidant effects via cannabinoid receptor-independent
mechanisms [163,167]. By contrast, selective CB1 or CB2 agonists failed to protect these
neurons [163].
5.1.3. Cannabinoids as anti-inflammatory agents
Substantial evidence supports that inflammation plays a pivotal role in the death of neurons
in the BG in PD. Activated microglia has been found in post-mortem brains from patients with
PD [168] and elevated levels of inflammatory cytokines have been measured in the cerebro‐
spinal fluid of patients [169–171]. Cannabinoid compounds have demonstrated anti-inflam‐
matory properties. Concretely, CB2 receptor agonists are the most promising cannabinoids to
treat the inflammatory processes related to neurodegenerative disorders, although other
cannabinoid agonists have also showed anti-inflammatory activity [172]. In fact, the selec‐
tive CB1 receptor agonist arachidonoyl-2-chloroethylamide and other non-selective cannabi‐
noid agonists have revealed strong anti-inflammatory properties [173].
CB2 receptor is expressed on microglia and it is strongly up-regulated when these cells are
activated [174]. In vitro activation of microglial CB2 receptors leads to suppression of the release
of pro-inflammatory cytokines reducing neurotoxicity [175]. The beneficial effect of CB2
receptor stimulation has also been proved in animal models of PD [161,165]. Moreover, an
increase of sensitivity to the neurotoxin LPS in CB2 receptor knockout mice has been descri‐
bed [165] and the overexpression of this receptor subtype reduced the recruitment of glial cells
to the lesion and decreased the level of various oxidative parameters [176].
Apart from the CB2 receptor, several studies have corroborated the anti-inflammatory
potential of targeting CB1 receptor in PD. WIN 55,212-2 or HU 210 administration decreases
the number of activated microglia and reduces the mRNA levels of the proinflammatory
cytokine IL-6 in MPTP mice and LPS-treated rats [162,177,178]. In another study, 2 week pre-
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treatment with ∆9-THC and CBD, followed by 6-OHDA injection, decreased the loss of
dopaminergic neurons in hemiparkinsonian rats [160].
All these studies suggest that the CB1 and CB2 receptors could be potential targets for anti-
inflammatory intervention in PD.
5.2. Huntington’s disease
To date, the treatment of HD is merely symptomatic and focuses on the restoration of the
neurotransmitter imbalance that occurs in the disease. For this reason, GABA agonists,
dopamine depleting agents, neuroleptics, anti-glutamatergic agents, antidepressants or
acetylcholinesterase inhibitors are often used for ameliorating the symptoms (for review see
[179]), despite not being able to cure or stop the progression of the disease. In this situation
cannabinoid compounds may play a promising therapeutic role as it has been proven in other
neurodegenerative diseases [180,181]. Indeed, activation of cannabinoid receptors facilitates
the activation of intracellular mechanisms related to cell homeostasis, repair and survival.
Moreover, several pre-clinical and clinical studies have showed that cannabinoids can be
useful in HD. The effects of cannabinoid compounds on HD can be divided in three differ‐
ent actions: improvement of motor symptoms, neuroprotection and anti-inflammatory
activity.
5.2.1. Cannabinoids for the treatment of motor symptoms
As mentioned above, the most characteristic feature of HD is the motor impairment which
varies along the progression of the disease. In this context, cannabinoid compounds have been
tested for treating these motor symptoms in animal models of HD, some of them showing anti-
hyperkinetic activity. The administration of the endocannabinoid re-uptake inhibitor, AM404,
reduced hyperkinetic movements and restored the neurochemical alterations (dopamine and
GABA reduction) in the HD rat model with bilateral striatal injection of 3-NP [130]. However,
the anti-hyperkinetic effect showed by AM404 seems to be mainly consequence of TRPV1
receptor activation, and not CB1-dependent [130]. In the same rat model of HD, the adminis‐
tration of UCM707, another endocannabinoid uptake inhibitor, also showed anti-hyperkinet‐
ic activity that may be due to the recovery of GABAergic and glutamatergic function in the GP
and SN, respectively [182]. In addition, Arvanil, a hybrid endocannabinoid and vanilloid
compound, has also demonstrated anti-hyperkinetic activity, although it could not restore the
neurochemical alterations in the 3-NP rat model of HD [183]. Similarly, the CB1 receptor
agonist CP55,940 has showed anti-hyperkinetic activity, without changing dopamine and
GABA levels [184]. Other compounds, VDM11 (endocannabinoid re-uptake inhibitor) and
AM374 (endocannabinoid hydrolysis inhibitor), have not demonstrated any significant effect
on hyperkinetic movements in the same HD model [184]. The chronic, but not the acute
administration of the CB1 receptor agonist WIN 55,212-2 prevented the appearance of motor
impairment in the R6/1 transgenic mice model of HD, without improving the social and
cognitive deficits [185]. So far, the clinical use of plant-derived cannabinoids and synthetic
analogues has shown disappointing results in the treatment of the motor symptoms. A case
report and a pilot study of nabilone in patients with HD showed that the effect of this drug on
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HD motor symptoms is limited [186,187]. Other studies have demonstrated that the adminis‐
tration of nabilone or CBD did not improve the hyperkinetic alterations associated with HD
[188,189]. The lack of therapeutic efficacy may lie on the mechanism of action of the cannabi‐
noid agonists used. These cannabinoid drugs were unable to activate TRPV1 receptors, which
have been proven to mediate anti-hyperkinetic in 3-NP-lesioned rats. Thus, the most appro‐
priate compounds for future clinical trials, at least in the early stages of the disease, may be
those able to activate both CB1 and TRPV1 receptors [190].
5.2.2. Cannabinoids as neuroprotective agents
The neuroprotective properties of the cannabinoids make them very interesting tools to stop
the progression of HD. In fact, cannabinoid compounds may reduce cytotoxic processes that
occur in neurons and glial cells in neurodegenerative diseases [181]. The protective effects are
consequence of the intracellular signaling pathways activated by cannabinoid compounds
[116], and are mediated by the activation of CB1, CB2 or TRPV1 receptors, but also due to CB
receptor independent processes [172].
Cannabinoid CB1 receptors are located in neuronal glutamatergic terminals at presynaptic and
postsynaptic levels. The activation of these receptors by cannabinoid agonists decreases
glutamate release and limits the glutamatergic excitotoxicity in neurodegenerative processes
[172]. Furthermore, CB1 receptor stimulation activates the phosphatidylinositol 3-kinase/Akt/
mammalian target of rapamycin complex 1 pathway, protecting cells from excitotoxic damage,
and facilitating brain-derived neurotrophic factor (BDNF) release [191]. The activation of CB1
receptors also diminishes the activity of voltage-sensitive calcium channels [192], reducing
calcium dependent damaging pathways. Moreover, cannabinoid compounds activating CB1
receptors are also involved in some other mechanisms related to cell protection and survival,
such as GABAergic signaling [193,194] or blood supply to lesioned brain areas [195]. On the
other hand, CB2 receptors are mainly located in glial cells and their activation also supports
cannabinoids-mediated neuroprotection. In fact, CB2 receptor activation reduces cytotoxic
factors release and generation of reactive oxygen and nitric oxide-derived substances [10].
However, cannabinoids also induce CB receptor independent neuroprotective mechanisms.
Some cannabinoid compounds can act on NMDA glutamatergic receptors, reducing high
glutamate levels at postsynaptic levels and excitotoxicity. Moreover, cannabinoids restore the
balance between oxidative and antioxidant mechanisms, mainly, by blocking reactive oxygen
substances [196] but also facilitating endogenous antioxidant activity [163,197].
Several pre-clinical studies have been performed to clarify the role of cannabinoids in CB1
receptors mediated neuroprotection in HD. In PC12 cells expressing HTT, CB1 receptor
stimulation showed different effects. Activation of CB1 receptors, coupled to Gi/o, induced
cell protection by inhibiting cAMP and ERK phosphorylation. However, CB1 receptors could
also couple to Gs, which stimulated cAMP and favored cell death in this HD model [198].
Similar results were also obtained in the in vitro model of striatal SPNs expressing wild-type
(STHdhQ7/Q7) or mutant HTT (STHdhQ111/Q111) [199]. Studies in rodent models of HD have
showed that cannabinoid compounds acting on CB1 receptors can reduce or delay the
neurodegeneration associated with this disease [116]. The striatal injection of quinolinic acid
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in rats increases the glutamatergic transmission, and therefore, the excitotoxicity, mimicking
some of the characteristic features of HD [200]. In this rat model of HD, the administration of
the CB1 receptor agonist WIN 55,212-2 diminished the increment of glutamate levels in‐
duced by the quinolinic acid. In addition, WIN 55,212-2 also reduced the effect of quinolinic
acid on corticostriatal local field potential recordings in vitro. The effects of WIN 55,212-2 were
blocked by the CB1 receptor antagonist AM 251, demonstrating that the effects observed were
CB1-dependent [200]. Thus, WIN 55,212-2 protected the striatum from the damage induced
by quinolinic acid, although, this CB1 receptor agonist could not modify the motor abnormal‐
ities induced by quinolinic acid [200]. In R6/2 mice, the administration of the ∆9-THC im‐
proved the symptoms, the neuropathology and the molecular pathology related to this HD
model, and induced BDNF expression in the striatum [119]. Moreover, the depletion of CB1
receptors in these transgenic mice impaired all the pathological features expressed by this HD
model, and reduced BDNF expression [119]. Additionally, in R6/2 mice, the striatal injection
of a recombinant adeno-associated viral vector encoding CB1 receptor induced the expres‐
sion of CB1 receptors and BDNF and normalized the molecular pathological signs observed
in this well established transgenic mice model of HD [191]. Interestingly, genetic rescue of CB1
receptors in the SPNs prevented the loss of vesicular glutamate transporter 1 and 2 (VGLUT1
and VGLUT2) and synaptophysin in the striatum, although it did not improve the motor
phenotype expressed by R6/2 mice [136]. Moreover, enriched environment delayed the onset
of motor alterations and the loss of CB1 receptors in R6/1 mice, slowing the progression of the
disease [201,202]. All these studies support the role of CB1 receptors and CB1 agonists as useful
therapeutic tools to reduce or delay the progression of HD. However, not all the studies have
showed that CB1 receptor agonists induce protective effects. Indeed, chronic administration
of HU210, ∆9-THC or URB597 did not modify the progressive impairment of motor activity in
the transgenic R6/1 mice model of HD [203]. Additionally, in the malonate-lesioned rat model
of HD, the administration of UCM707 did not delay the degeneration observed in this
model [182]. Thus, further studies are needed to investigate and clarify the implication of CB1
receptors in HD and the potential therapeutic effects of CB1 receptor agonists.
Cannabinoid compounds that activate CB2 receptors have showed neuroprotective effects in
HD [139]. The administration of the CB2 receptor agonist HU-308 in the quinolinic acid-
lesioned mice attenuated glial activation and reduced the neuronal damage in the striatum
[137]. Likewise, in the malonate-lesioned rat model of HD, the administration of the selec‐
tive CB2 receptor agonist HU-308 protected striatal neurons from the apoptotic mechanisms
activated by malonate [139]. This neuroprotection was blocked by the administration of the
selective CB2 receptor antagonist SR144528, ratifying that the effect observed was CB2-
dependent [139]. The neuroprotective effects of CB2 receptor agonists are associated with the
reduction of the toxicity caused by reactive microglial cells [116,137]. The activation of CB2
receptors can also induce the expression of pro-survival substances [10,204]. In contrast, CB2
receptor-deficient R6/2 mice showed accelerated progression of the HD phenotype ex‐
pressed by this model [137]. In fact, the ablation of CB2 receptors in these mice increased the
glial activation and the sensitivity to striatal neurodegeneration induced by excitotoxic
processes [137]. Thus, both in genetic and in toxin-lesioned rodent models of HD cannabi‐
noids displayed CB2 receptor mediated protective effects [137,139].
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Finally, cannabinoid compounds may also exert neuroprotective effects independent of CB1
or CB2 receptor activation in animal models of HD. This CB receptor independent protec‐
tion displayed by some cannabinoids (i.e. ∆9-THC or CBC) is related to the blockage of reactive
oxygen molecules [172]. The capacity to block reactive oxygen molecules may be due to the
phenolic structures of these cannabinoid compounds. Indeed, in 3-NP-lesioned rat model of
HD, the administration of CBC reduced the striatal atrophy produced by this toxin [197]. Thus,
cannabinoid compounds may be useful to protect cells from the cytotoxicity associated with
oxidative processes.
As mentioned above, clinical studies have been developed to examine the effect of cannabi‐
noids on HD. However, most of these studies were designed to analyze the effect of specific
cannabinoid compounds on specific symptoms, and not to study the neuroprotective effect of
cannabinoids [116]. Moreover, results obtained from animal models of HD have showed that
combination of cannabinoids can be more useful to protect neurons than single cannabi‐
noids [116]. In fact, Sativex®, a combination of ∆9-THC and CBC, has showed protective effect
on striatal neurons in some rodent models of HD [205,206]. A clinical trial in patients with HD
concluded that Sativex® was safe and well tolerated, but it was not able to stop or slow the
progression of the neurodegeneration (see https://clinicaltrials.gov/ct2/show/NCT01502046).
5.2.3. Cannabinoids as anti-inflammatory agents
As mentioned before, CB2 receptors are mainly located in glial cells, and are poorly ex‐
pressed in the striatum in healthy condition. However, the striatal expression of these recep‐
tors is increased in patients with and animal models of HD. In HD, the reactive microglia
may release inflammatory cytokines, reactive oxygen substances or nitric oxide [10,207,208].
Cannabinoid compounds activating CB2 receptors in glial cells can reduce the release of
these factors, and promote the release of some anti-inflammatory cytokines (i.e. IL-10,
IL-1ra) [209,210]. Moreover, it has been demonstrated that CB2 receptor agonists improve
striatal inflammation in different rodent models of HD [137,139]. Interestingly, CB2 recep‐
tors are not involved in the psychotrophic effects induced by cannabinoid compounds. This
property makes CB2 receptor agonists valuable compounds for future therapeutic ap‐
proaches in HD.
6. Concluding remarks
To date, vast number of preclinical evidence have demonstrated that the ECS controls the
motor activity in both physiological and pathological states. Cannabinoid compounds have
been proven to ameliorate motor symptoms and drug-induced side effects. In addition, the
anti-inflammatory and neuroprotective properties of these agents make them promising
drugs to delay the progression of neurodegenerative diseases. For these reasons, further ba‐
sic and clinical cannabis-based research could bring a new light into the treatment of move‐
ment disorders, such as PD and HD.
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